Senior Science Editor
at Technology Networks
After obtaining a first-class honors degree in biological sciences from the University of East Anglia, Anna worked as a scientific conference producer before joining Technology Networks. As part of her role, Anna helps to coordinate coverage, working with key opinion leaders from industry and academia to produce content across all communities.
Education
Areas of Expertise
Got a Question for Anna MacDonald?
Get in touch using the contact form linked here and we’ll get back to you shortly.
Published Content
Total: 328
Industry Insight
Harnessing the Therapeutic Potential of Muscimol
Technology Networks recently spoke with Jeff Stevens, Psyched Wellness’s CEO, to learn more about muscimol, its therapeutic potential and how it compares to other psychedelics such as psilocybin.
Industry Insight
Non-Hallucinogenic Psychedelic Analogs Could Be Game Changers for Neuropsychiatry
In this interview, David E. Olson discusses the potential commercial, clinical and scientific implications of non-hallucinogenic psychedelic compounds.
Industry Insight
How CRISPR-Based Gene Engineering Is Helping To Accelerate Alzheimer’s Disease Research
To learn about some of the main challenges associated with generating a large library of edited iPSCs and the role that Synthego is playing in the iNDI project, we spoke to Synthego’s CSO, Dr Robert Dean.
Industry Insight
Shaping the Future of Organoid Research
Molecular Devices recently unveiled a brand new, first-of-its-kind Organoid Innovation Center. In this interview, Susan Murphy tells us more about the Center and discusses the advantages of automating organoid culturing and screening workflows.
Industry Insight
Trends, Applications and Advances in Spatial Transcriptomics
In this interview, Dr George Emanuel discusses the power of spatial transcriptomic profiling and some of the biggest trends in the field.
Industry Insight
The Ins and Outs of Psychedelic-Assisted Psychotherapy
To learn more about psychedelic-assisted psychotherapy, the advantages it offers and some of the conditions it could help to treat, Technology Networks spoke with Dr Reid Robison, chief medical officer of Novamind, a mental health company specialized in psychedelic medicine.
Industry Insight
Next-Generation Sequencing for SARS-CoV-2 Surveillance
To gain some insights into the role of NGS in global SARS-CoV-2 surveillance, we spoke to Michelle Fraser, general manager, NGS for PerkinElmer. Michelle also explains how labs working in this area can increase their throughput, decrease associated costs and simplify the analysis of NGS data collected.
Industry Insight
Advancing Research of Inflammatory Intestinal Diseases
We spoke to Dr Lorna Ewart, Emulate’s executive vice president of science, to learn more about the limitations of traditional inflammatory intestinal disease models, what makes the Colon Intestine-Chip a more relevant model and how it can be used to investigate potential drug targets.
Industry Insight
Harnessing T Cells To Detect Disease
In this interview, Dr Sudeb Dalai, senior medical director at Adaptive Biotechnologies, discusses the role that T-cell analysis may play in the diagnosis and treatment of diseases including SARS-CoV-2.
Infographic
Culturing Cells for Cancer Research
Cell culture is an invaluable tool for cancer research, used in studies to improve our understanding of fundamental cancer biology and as preclinical models to develop and test drugs. For several years, cell lines have helped uncover many intricacies of cancer pathogenesis, providing a simple, low cost and rapid way to test hypotheses.
Advertisement
